Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer
This is a single-arm, interventional study aimed to observe the efficacy and safety of Apatinib combined with S-1 for patients with advanced gastric cancer refractory to oxaliplatin plus capecitabine combination therapy
Gastric Cancer
DRUG: Apatinib Mesylate tablets combined with S-1 capsules
median progression-free survival(mPFS), The median duration of time between when a patient with oncological disease receives treatment and when the disease progresses or death due to any cause occurs., 2 years|median overall survival(mOSï¼‰, The median time from treatment to the last follow-up or death., 2 years
objective response rate(ORR), The rate of patients achieved complete response or partial response, 2 years|disease control rate(DCR) DCR, The rate of patients achieved complete response or partial response or solid disease., 2 years
This is a single-arm, interventional study aimed to observe the efficacy and safety of Apatinib combined with S-1 for patients with advanced gastric cancer refractory to oxaliplatin plus capecitabine combination therapy